Details of the Drug

General Information of Drug (ID: DMPIBJK)

Drug Name
Propafenone
Synonyms
Propafenona; Propafenonum; Rythmol; Propafenon Hexal; Propafenon hexal (TN); Propafenona [INN-Spanish]; Propafenone (INN); Propafenone [INN:BAN]; Propafenone-HCl; Propafenonum [INN-Latin]; Rythmol SR (TN); Rytmonorm (TN); 1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; 1-(2-(2-Hydroxy-3-propylaminopropoxy)phenyl)-3-phenylpropan-1-one; 1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride; 1-[2-(2-Hydroxy-3-[propylamino]-propoxy)phenyl]-3-phenyl-1-propanone; 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one
Indication
Disease Entry ICD 11 Status REF
Tachyarrhythmias BC71 Approved [1], [2]
Therapeutic Class
Antiarrhythmic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 341.4
Topological Polar Surface Area (xlogp) 3.3
Rotatable Bond Count (rotbonds) 11
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 16 mL/min/kg [4]
Elimination
0.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 10 hours [4]
Metabolism
The drug is metabolized via the liver [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.038% [4]
Vd
The volume of distribution (Vd) of drug is 252 L [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.093 mg/mL [3]
Chemical Identifiers
Formula
C21H27NO3
IUPAC Name
1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one
Canonical SMILES
CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
InChI
InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3
InChIKey
JWHAUXFOSRPERK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4932
ChEBI ID
CHEBI:63619
CAS Number
54063-53-5
DrugBank ID
DB01182
TTD ID
D0J2KV
VARIDT ID
DR00634
INTEDE ID
DR1361
ACDINA ID
D00562

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
E3 ubiquitin-protein ligase COP1 (RFWD2) TT05DLS COP1_HUMAN Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [9]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Propafenone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Propafenone and Flecainide. Ventricular tachyarrhythmia [BC71] [44]
Coadministration of a Drug Treating the Disease Different from Propafenone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Propafenone and Ivosidenib. Acute myeloid leukaemia [2A60] [45]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Propafenone and Midostaurin. Acute myeloid leukaemia [2A60] [44]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Propafenone and Arn-509. Acute myeloid leukaemia [2A60] [46]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Propafenone and Gilteritinib. Acute myeloid leukaemia [2A60] [47]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Propafenone and Oliceridine. Acute pain [MG31] [44]
Emapalumab DMZG5WL Moderate Altered metabolism of Propafenone due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [46]
Siltuximab DMGEATB Moderate Altered metabolism of Propafenone due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [46]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Propafenone and Ivabradine. Angina pectoris [BA40] [46]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Propafenone and Bepridil. Angina pectoris [BA40] [48]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Propafenone and Dronedarone. Angina pectoris [BA40] [44]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Propafenone and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [49]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Propafenone and Posaconazole. Aspergillosis [1F20] [44]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Levalbuterol. Asthma [CA23] [50]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Pirbuterol. Asthma [CA23] [51]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Propafenone caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [46]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [46]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Propafenone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [52]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Propafenone and Clarithromycin. Bacterial infection [1A00-1C4Z] [44]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Propafenone and Sparfloxacin. Bacterial infection [1A00-1C4Z] [53]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Propafenone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [52]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Propafenone and Retigabine. Behcet disease [4A62] [44]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Propafenone and Eribulin. Breast cancer [2C60-2C6Y] [44]
Talazoparib DM1KS78 Moderate Decreased clearance of Propafenone due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [46]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Propafenone and Lapatinib. Breast cancer [2C60-2C6Y] [44]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Propafenone and Bosutinib. Breast cancer [2C60-2C6Y] [46]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Propafenone and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [54]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Propafenone and Olodaterol. Chronic obstructive pulmonary disease [CA22] [51]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Propafenone and Vilanterol. Chronic obstructive pulmonary disease [CA22] [50]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Indacaterol. Chronic obstructive pulmonary disease [CA22] [51]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Arformoterol. Chronic obstructive pulmonary disease [CA22] [51]
Fidaxomicin DMFP6MV Minor Decreased clearance of Propafenone due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [55]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Sevoflurane. Corneal disease [9A76-9A78] [44]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Propafenone and Probucol. Coronary atherosclerosis [BA80] [44]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Propafenone and Pasireotide. Cushing syndrome [5A70] [44]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Propafenone and Osilodrostat. Cushing syndrome [5A70] [46]
MK-8228 DMOB58Q Moderate Decreased metabolism of Propafenone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [52]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Propafenone and Clomipramine. Depression [6A70-6A7Z] [56]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Propafenone and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [44]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Propafenone and Deutetrabenazine. Dystonic disorder [8A02] [57]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Propafenone and Ingrezza. Dystonic disorder [8A02] [58]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Propafenone and Solifenacin. Functional bladder disorder [GC50] [44]
Mirabegron DMS1GYT Moderate Decreased metabolism of Propafenone caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [59]
Ripretinib DM958QB Moderate Decreased clearance of Propafenone due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [60]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Propafenone and Sunitinib. Gastrointestinal stromal tumour [2B5B] [44]
Boceprevir DMBSHMF Moderate Decreased metabolism of Propafenone caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [52]
Simeprevir DMLUA9D Moderate Decreased metabolism of Propafenone caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [61]
Telaprevir DMMRV29 Moderate Decreased metabolism of Propafenone caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [52]
Rifapentine DMCHV4I Moderate Increased metabolism of Propafenone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [62]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Propafenone caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Propafenone and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [63]
Cobicistat DM6L4H2 Major Decreased metabolism of Propafenone caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Saquinavir DMG814N Major Decreased metabolism of Propafenone caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Etravirine DMGV8QU Moderate Increased metabolism of Propafenone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Propafenone and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [44]
Darunavir DMN3GCH Moderate Decreased metabolism of Propafenone caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Acebutolol DM0TI4U Moderate Decreased metabolism of Propafenone caused by Acebutolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [67]
Aliskiren DM1BV7W Moderate Decreased clearance of Propafenone due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [44]
Penbutolol DM4ES8F Moderate Decreased metabolism of Propafenone caused by Penbutolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [67]
Nebivolol DM7F1PA Moderate Decreased metabolism of Propafenone caused by Nebivolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [67]
Tolvaptan DMIWFRL Moderate Decreased clearance of Propafenone due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [68]
Givosiran DM5PFIJ Moderate Decreased metabolism of Propafenone caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [69]
Berotralstat DMWA2DZ Major Decreased clearance of Propafenone due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [70]
Amobarbital DM0GQ8N Minor Increased metabolism of Propafenone caused by Amobarbital. Insomnia [7A00-7A0Z] [71]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Propafenone caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [72]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Propafenone and Polyethylene glycol. Irritable bowel syndrome [DD91] [46]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Propafenone and Phenolphthalein. Irritable bowel syndrome [DD91] [44]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Propafenone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [46]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Propafenone and Crizotinib. Lung cancer [2C25] [73]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Propafenone and Ceritinib. Lung cancer [2C25] [44]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Propafenone caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [74]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Propafenone and Osimertinib. Lung cancer [2C25] [75]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Propafenone and Selpercatinib. Lung cancer [2C25] [46]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Propafenone and Lumefantrine. Malaria [1F40-1F45] [60]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Propafenone and Halofantrine. Malaria [1F40-1F45] [76]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Propafenone and Hydroxychloroquine. Malaria [1F40-1F45] [77]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [46]
Idelalisib DM602WT Moderate Decreased metabolism of Propafenone caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [52]
GDC-0199 DMH0QKA Major Decreased clearance of Propafenone due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [60]
Arry-162 DM1P6FR Moderate Decreased clearance of Propafenone due to the transporter inhibition by Arry-162. Melanoma [2C30] [60]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Propafenone and Vemurafenib. Melanoma [2C30] [44]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Propafenone and LGX818. Melanoma [2C30] [78]
Ubrogepant DM749I3 Moderate Decreased clearance of Propafenone due to the transporter inhibition by Ubrogepant. Migraine [8A80] [79]
Rimegepant DMHOAUG Moderate Decreased clearance of Propafenone due to the transporter inhibition by Rimegepant. Migraine [8A80] [80]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Propafenone and Panobinostat. Multiple myeloma [2A83] [81]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Propafenone and Siponimod. Multiple sclerosis [8A40] [60]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Propafenone and Fingolimod. Multiple sclerosis [8A40] [44]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Propafenone and Ozanimod. Multiple sclerosis [8A40] [82]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Propafenone and Romidepsin. Mycosis fungoides [2B01] [44]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Propafenone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [52]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Propafenone and Nilotinib. Myeloproliferative neoplasm [2A20] [44]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Propafenone and Dasatinib. Myeloproliferative neoplasm [2A20] [83]
Rolapitant DM8XP26 Moderate Decreased metabolism of Propafenone caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [84]
Netupitant DMEKAYI Moderate Decreased metabolism of Propafenone caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [52]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Propafenone and Entrectinib. Non-small cell lung cancer [2C25] [60]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Propafenone caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [85]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Propafenone and Levomethadyl Acetate. Opioid use disorder [6C43] [46]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Lofexidine. Opioid use disorder [6C43] [44]
Olaparib DM8QB1D Moderate Increased metabolism of Propafenone caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [60]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Rucaparib. Ovarian cancer [2C73] [44]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Propafenone and Triclabendazole. Parasitic worm infestation [1F90] [44]
Rasagiline DM3WKQ4 Moderate Decreased metabolism of Propafenone caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [60]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Propafenone and Pimavanserin. Parkinsonism [8A00] [86]
Abametapir DM2RX0I Moderate Decreased metabolism of Propafenone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [87]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Propafenone and Macimorelin. Pituitary gland disorder [5A60-5A61] [88]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Propafenone and Lefamulin. Pneumonia [CA40] [89]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Propafenone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [52]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Propafenone and Degarelix. Prostate cancer [2C82] [46]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Propafenone caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [90]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Propafenone and Enzalutamide. Prostate cancer [2C82] [46]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Propafenone and Relugolix. Prostate cancer [2C82] [91]
Darolutamide DMV7YFT Minor Decreased clearance of Propafenone due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [92]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Propafenone due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [46]
Ixekizumab DMXW92T Moderate Altered metabolism of Propafenone due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [46]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Propafenone and Levomepromazine. Psychotic disorder [6A20-6A25] [44]
Everolimus DM8X2EH Moderate Decreased clearance of Propafenone due to the transporter inhibition by Everolimus. Renal cell carcinoma [2C90] [93]
Tocilizumab DM7J6OR Moderate Altered metabolism of Propafenone due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [46]
Canakinumab DM8HLO5 Moderate Altered metabolism of Propafenone due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [46]
Rilonacept DMGLUQS Moderate Altered metabolism of Propafenone due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [46]
Golimumab DMHZV7X Moderate Altered metabolism of Propafenone due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [46]
Sarilumab DMOGNXY Moderate Altered metabolism of Propafenone due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [46]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Propafenone and Quetiapine. Schizophrenia [6A20] [44]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Propafenone caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [60]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Propafenone and Iloperidone. Schizophrenia [6A20] [44]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Propafenone and Paliperidone. Schizophrenia [6A20] [44]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Propafenone and Amisulpride. Schizophrenia [6A20] [94]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Asenapine. Schizophrenia [6A20] [44]
Larotrectinib DM26CQR Moderate Decreased clearance of Propafenone due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [60]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Propafenone and LEE011. Solid tumour/cancer [2A00-2F9Z] [44]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Propafenone and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [44]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Propafenone and Pitolisant. Somnolence [MG42] [44]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Propafenone and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [44]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Propafenone due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [95]
Apixaban DM89JLN Moderate Decreased clearance of Propafenone due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [46]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Propafenone and Lenvatinib. Thyroid cancer [2D10] [44]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Propafenone and Cabozantinib. Thyroid cancer [2D10] [46]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Propafenone and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [96]
⏷ Show the Full List of 136 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd E00585 56841934 Colorant
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
⏷ Show the Full List of 32 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Propafenone 425 mg capsule 425 mg 12 HR Extended Release Oral Capsule Oral
Propafenone 225 mg capsule 225 mg 12 HR Extended Release Oral Capsule Oral
Propafenone 325 mg capsule 325 mg 12 HR Extended Release Oral Capsule Oral
Propafenone 300 mg tablet 300 mg Oral Tablet Oral
Propafenone 150 mg tablet 150 mg Oral Tablet Oral
Propafenone 225 mg tablet 225 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2561).
2 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol. 2000 Aug;20(4):428-34.
10 Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol. 1998 Apr;45(4):361-8.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
21 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
22 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
23 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
24 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
25 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
26 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
27 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
28 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
29 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
30 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
31 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
32 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
33 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
34 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
35 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
36 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
37 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
38 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
39 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
40 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
41 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
42 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
43 Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle. Am Heart J. 1990 May;119(5):1050-60.
44 Canadian Pharmacists Association.
45 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
46 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
47 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
48 Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8. [PMID: 4043097]
49 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
50 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
51 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
52 Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.
53 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
54 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
55 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
56 Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]
57 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
58 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
59 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
60 Cerner Multum, Inc. "Australian Product Information.".
61 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
62 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
63 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
64 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
65 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
66 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
67 Ahmad S "Metoprolol-induced delirium perpetuated by propafenone." Am Fam Physician 44 (1991): 1142,4. [PMID: 1927831]
68 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
69 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
70 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
71 Sams RA, Muir WW. Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. Am J Vet Res. 1988;49(2):245-249. [PMID: 3348533]
72 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
73 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
74 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
75 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
76 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
77 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
78 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
79 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
80 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
81 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
82 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
83 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
84 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
85 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
86 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
87 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
88 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
89 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
90 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
91 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
92 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
93 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
94 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
95 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
96 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]